• 2009 Program

• 2009 Block Program

• 2009 Speakers

PROGRAM QUESTIONS?

Rebecca Angelos
Conference Director

Phone:
+1.831.464.4230 x153

testimonial

“Able to see what many of the VC's are looking for with the changing economic environment. Ability to learn from other companies on what makes a quality presentation. Excellent networking opportunities for partnerships, funding and M&A.

- Shawn P. O'Brien

 Profectus BioSciences

5:00-6:30  Registration - Meritage Lobby

Visit the registration desk to check in on Tuesday which allows you to jump-start your networking opportunities at the Welcome Drinks Reception in the Meritage Resort Estate Wine Cave.

By registering early, you'll be able to collect your name badge, program, and handbag materials and avoid long lines on Wednesday morning.

5:00-6:30  Welcome Drinks Reception - Estate Wine Cave

Sponsored by:

Connect with fellow delegates on Tuesday evening before C21 BioVentures begins, over drinks and appetizers in the Estate Wine Cave at the Meritage Resort. The beautiful natural stone and dark woods combined with Old World Florentine architecture and furnishings will offer you an environment unlike any other

8:30-9:30  Continental Breakfast - Vineyard Terrace

Join us for a continental breakfast of fresh fruit juices, breakfast pastries accompanied by sweet cream butter and fruit preserves, sliced seasonal fruits and berries, and an assortment of yogurts. Freshly brewed coffee, decaffeinated coffee, breakfast and herbal teas will also be available.

8:30-5:00  Registration - Meritage Lobby

9:15-9:30  Conference Welcome - Salons VII - X

In its 11th year, Technology Vision Group and BayBio are wholly committed to make it possible for private life science companies and their investors to build value, at C21. Holding an event in this climate is a tremendous achievement!

 

As we continue to evolve along with the state of bioventure investing, our purpose is to create an environment which allows private life science company executives to partner, raise capital, and network in a single venue. C21 brings together private investors, pharmaceutical companies, biotechs large and small, as well as a number of leading service providers in a relaxed and enjoyable atmosphere. We believe it is possible to have fun while learning and networking at C21.

Speaker: Mr. Matthew M. Gardner, President and CEO, BayBio
Speaker: Dr. Robert Lee Kilpatrick, Partner, Technology Vision Group LLC

9:30-10:45  BioVenture Leadership Session - Salons VII - X

Title: Is This a Bump in the Road or a Fork? Biotech Markets – Whither the Future?

Since the 2008 Deloitte Life Sciences Investing Survey: “Venture capitalists’ views of industry challenges and opportunities”, the capital markets have rained down on the BioPharm emerging growth market. This storm has decimated public and private company valuations alike, while making it very difficult for companies to raise new capital. The Nuclear Winter, as some have termed the storm, has left many venture capitalists wondering if this is a very large bump in the road or a completely new road.

In search of answers, Deloitte conducted in person and telephone interviews with leading venture capitalists in late February and early March 2009. Many of these venture capitalists are members of the C21 Advisory Board. In this session, we will explore the results of the 2009 Deloitte Life Sciences Investing Survey and hear directly from some of the leading venture capitalists on trends, obstacles and innovative strategies to succeed in this market.

Chair: Mr. Eric Walczykowski, Venture Capital Services, Deloitte
Speaker: Dr. Stuart J.M. Collinson, Key Voting Member, Forward Ventures
Speaker: Mr. Chris Ehrlich, General Partner, InterWest Partners
Speaker: Dr. Heather Preston, Managing Partner, TPG Biotech
Speaker: Dr. Ilan D. Zipkin, Partner, Prospect Venture Partners

10:45-4:30  Coffee & Tea Service - Vineyard Pre-Function Area

11:15-1:00  Company Presentations - Stream 1 - Salon VI

In these dedicated presentations, biotechnology companies from around the world have the opportunity to briefly introduce their company, highlight key technologies, alliances, and where they stand with product & clinical developments.

11:15 VLST Corporation - USA
11:30 Armune BioScience, Inc. - USA
11:45 Kalgene Pharma Inc. - Canada
12:00 Marillion Pharmaceuticals - USA
12:15 MBC Pharma, Inc - USA
12:30 Biothera - USA
12:45 VentiRx Pharmaceuticals - USA

11:15-1:00  Company Presentations - Stream 2 - Salon IV

In these dedicated presentations, biotechnology companies from around the world have the opportunity to briefly introduce their company, highlight key technologies, alliances, and where they stand with product & clinical developments.

11:15 NanoMed Pharmaceuticals, Inc. - USA
11:30 KAI Pharmaceuticals Inc. - USA
11:45 Vaxart - USA
12:00 Caprotec GmbH - Germany
12:15 Single Cell Technology - USA
12:30 Milestone Pharmaceuticals - Canada
12:45 Lux Biosciences Inc - USA

11:30-1:30  Presenting Company Tabletop Meetings - Salon II

Companies will be available for informal face-to-face meetings for 30 minutes immediately following their presentation time.

Company	Table #	Table Time
Armune BioScience, Inc.	3	11:45-12:15
Biothera	5	12:45-1:15
Caprotec GmbH	2	12:15-12:45
KAI Pharmaceuticals Inc.	4	11:45-12:15
Kalgene Pharma Inc.	5	12:00-12:30
Lux Biosciences Inc	2	1:00-1:30
Marillion Pharmaceuticals	1	12:15-12:45
MBC Pharma, Inc	3	12:30-1:00
Milestone Pharmaceuticals	6	12:45-1:15
NanoMed Pharmaceuticals, Inc.	2	11:30-12:00
Single Cell Technology	4	12:30-1:00
Vaxart	6	12:00-12:30
VentiRx Pharmaceuticals	1	1:00-1:30
VLST Corporation	1	11:30-12:00

1:00-2:00  Hot Lunch Buffet - Vineyard Terrace & Estate Wine Cave

Revitalize yourself with a hearty lunch of Napa Valley coleslaw, grilled summer vegetables, new potato salad, cumin scented salmon with roasted tomato salsa, chipotle BBQ tri-tip beef, and foccacia and sandwich rolls. Finish your delightful lunch with a refreshing serving of Madeira macerated berries.

2:00-3:15  Trends & Issues Session 1 - Salons VII - X

Title: What happens in biotech partnering and licensing deals when things go wrong… and how to protect yourself

These complex deals can go wrong in many ways, especially in the current business climate. As long as results are good and both companies (and the economy) are healthy, contracts spend a lot of time sitting in drawers. The drawers open quickly when things go sideways, bad data come in, or the unexpected happens.

These agreements also see the light of day in due diligence for financings and new license and partnering projects, where prospective investors and collaborators look to see how well a young company -- and for partners, the shepherd of critical IP and other matters for a future product -- has contemplated the unexpected, and protected its value and the value of its products through thoughtful, well-crafted licenses and partnering terms. In these times, a period when even more unexpected things than usual are happening with many companies, we will explore key areas in licenses, collaborations and partnering deals where companies can protect themselves against the worst and the unexpected. These include diligence, termination, effect of termination, scope, acquisition and change of control clauses, and certain detailed financial terms, among other areas.

We will connect detailed provisions that are frequently not on anyone’s mind at the term sheet stage, but will come out in someone’s favor in the agreement (more likely in favor of whomever pays them the most attention), to the big picture, and provide suggestions as to how to make these provisions work in your favor under a range of scenarios. We will also identify key points companies can expect investors and partners to look at in in-licenses and existing partnering arrangements during due diligence and how to line things up for this pressure-testing to go well.

Chair: Ms. Laura O. Spiegelman, Partner, Morrison & Foerster LLP
Speaker: Dr. Kenneth Chahine, Chief Executive Officer and Director, Avigen, Inc.
Speaker: Mr. Jeff Jonker, Director of Business Development, Genentech Inc
Speaker: Mr. Raul R. Rodriguez, EVP and COO, Rigel, Inc.

2:00-5:30  Company Presentations - Stream 1 - Salon VI

In these dedicated presentations, biotechnology companies from around the world have the opportunity to briefly introduce their company, highlight key technologies, alliances, and where they stand with product & clinical developments.

2:00 NeoGenix Oncology, Inc. - USA
2:15 Axela Inc. - Canada
2:30 Nereus Pharmaceuticals Inc. - USA
2:45 Stellarray, Inc. - USA
3:00 Eureka Therapeutics, Inc. - USA
3:15 kDh Systems - USA
3:30 Nanospectra Biosciences - USA
3:45 BiPar Sciences, Inc - USA
4:00 Alios BioPharma - USA
4:15 Osprey Pharmaceuticals USA - USA
4:30 Mithridion Inc - USA
4:45 NewBridge Pharmaceuticals - USA
5:00 Fate Therapeutics - USA
5:15 ProteoTech Inc. - USA

2:15-6:00  Presenting Company Tabletop Meetings - Salon II

Companies will be available for informal face-to-face meetings for 30 minutes immediately following their presentation time.

Company	Table #	Table Time
Alios BioPharma	3	4:15-4:45
Axela Inc.	2	2:30-3:00
BiPar Sciences, Inc	2	4:00-4:30
Eureka Therapeutics, Inc.	2	3:15-3:45
Fate Therapeutics	1	5:15-5:45
kDh Systems	3	3:30-4:00
Mithridion Inc	2	4:45-5:15
Nanospectra Biosciences	1	3:45-4:15
NeoGenix Oncology, Inc.	1	2:15-2:45
Nereus Pharmaceuticals Inc.	3	2:45-3:15
NewBridge Pharmaceuticals	3	5:00-5:30
Osprey Pharmaceuticals USA	1	4:30-5:00
ProteoTech Inc.	2	5:30-6:00
Stellarray, Inc.	1	3:00-3:30

4:15-5:30  Trends & Issues Session 2 - Salons VII - X

Title: Structured Acquisitions: Win-Win or Lose-Lose?

Biopharma M&A transactions hit an all-time high in 2008, both in deal number and transaction value. With big pharma facing pipeline gaps and venture-backed biotechs needing capital, 2009 should be a robust year for M&A. Yet many potential deals have and will fall apart owing to the buyers’ natural reluctance to pay big upfronts ahead of near-term clinical results.

One way that buyers can hedge clinical risk is through highly structured acquisitions. Does such structuring create a win-win situation? Or do investors and entrepreneurs give away too much upside while buyers still assume too much risk? This session will look at upsides and pitfalls of structured acquisitions. The goal is to provide entrepreneurs and investors a better practical understanding of these transactions from the perspectives of key parties involved.

Chair: Dr. Jeff Calcagno, Principal & Kauffman Fellow, Scale Venture Partners
Speaker: Dr. Lutz Giebel, Managing Partner, SV Life Sciences
Speaker: Mr. Barclay J Kamb, Partner, Cooley Godward Kronish LLP
Speaker: Mr. Jim McLoughlin, Executive Director of Worldwide Business Development, Pfizer
Speaker: Mr. Art Pappas, Managing Partner, Pappas Ventures

6:00-6:30  Bus Transportation to Artesa Winery

Buses will depart from the front of the Resort. If you choose to drive, there is sufficient parking and the drive is approximately 15 minutes. Driving directions are available online or onsite at the registration desk.

Buses will shuttle between the hotel and the winery throughout the event. The last bus will depart from the winery at 8:45.

6:30-8:00  Dinner at Artesa Winery - Artesa Vineyards & Winery

Continue to network with delegates at the Artesa Winery, Napa’s newest, most exciting winery.  It is architecturally-acclaimed facility opened as Codorniu Napa in 1991, dedicated solely to method champenoise sparkling wine production.

8:00-9:00  Continental Breakfast - Vineyard Terrace

Join us for a continental breakfast of fresh fruit juices, breakfast pastries accompanied by sweet cream butter and fruit preserves, sliced seasonal fruits and berries, and an assortment of yogurts. Freshly brewed coffee, decaffeinated coffee, breakfast and herbal teas will also be available.

8:00-4:00  Registration - Meritage Lobby

8:30-9:45  Trends & Issues Session 3 - Salons VII - X

Title: There's Got To Be a Better Way: Can We Reinvent The Biotech Company Model?

This panel of experienced industry leaders will focus at a high and creative level on the question of whether the fundamental current biotech company and drug development model is truly broken, or perhaps even outmoded, today, whether there is a better way to do what needs to be done to get a biotech product from bench to bedside with less time, less money, and less failure, and if so, what that business model would look like and how we might implement it in today's financial and business environment.

Chair: Mr. Bruce W. Jenett, Partner & Co-Chair, Global Life Sciences Sector, DLA Piper LLP
Speaker: Mr. Jack Anthony, CEO, Osprey Pharmaceuticals USA
Speaker: Mr. Martin Babler, President and Chief Executive Officer, Talima Therapeutics
Speaker: Dr. Michael G. McCully, Senior Manager, Deloitte Recap LLC
Speaker: Mr. Fred M. Schwarzer, Managing Partner, Charter Life Sciences

8:30-12:15  Company Presentations - Stream 1 - Salon VI

In these dedicated presentations, biotechnology companies from around the world have the opportunity to briefly introduce their company, highlight key technologies, alliances, and where they stand with product & clinical developments.

8:30 NewLink Genetics Corporation - USA
8:45 ApopLogic Pharmaceuticals, LLC - USA
9:00 TNT Pharma - USA
9:15 KemPharm, Inc. - USA
9:30 Akebia Therapeutics - USA
9:45 LineaGen, Inc. - USA
10:00 Auspex Pharmaceuticals - USA
10:15 MyeloRx - USA
10:30 Cellular Dynamics International - USA
10:45 Melior Discovery, Inc. - USA
11:00 Presidio Pharmaceuticals, Inc. - USA
11:15 MiCardia - USA
11:30 Inimex Pharmaceuticals, Inc. - Canada
11:45 Numerate, Inc. - USA
12:00 AnaptysBio, Inc. - USA

8:45-12:45  Presenting Company Tabletop Meetings - Salon II

Companies will be available for informal face-to-face meetings for 30 minutes immediately following their presentation time.

Company	Table #	Table Time
Accera, Inc	2	11:45-12:15
Akebia Therapeutics	2	9:45-10:15
AnaptysBio, Inc.	5	12:15-12:45
ApopLogic Pharmaceuticals, LLC	2	9:00-9:30
Arzeda Corporation	5	10:45-11:15
Auspex Pharmaceuticals	1	10:15-10:45
Bellicum Pharmaceuticals, Inc	6	11:30-12:00
Cellular Dynamics International	4	10:45-11:15
Cytox Limited	2	11:00-11:30
Inimex Pharmaceuticals, Inc.	1	11:45-12:15
KemPharm, Inc.	1	9:30-10:00
LineaGen, Inc.	3	10:00-10:30
Logical Therapeutics, Inc.	6	12:15-12:45
Madeira Therapeutics	3	10:30-11:00
Melior Discovery, Inc.	1	11:00-11:30
MiCardia	5	11:30-12:00
MyeloRx	2	10:30-11:00
NewLink Genetics Corporation	1	8:45-9:15
Numerate, Inc.	3	12:00-12:30
Pepscan Therapeutics BV	4	11:15-11:45
Presidio Pharmaceuticals, Inc.	3	11:15-11:45
Somnus Therapeutics, Inc.	4	12:00-12:30
TNT Pharma	3	9:15-9:45

9:45-4:00  Coffee & Tea Service - Vineyard Pre-Function Area

10:15-12:15  Company Presentations - Stream 2 - Salon IV

In these dedicated presentations, biotechnology companies from around the world have the opportunity to briefly introduce their company, highlight key technologies, alliances, and where they stand with product & clinical developments.

10:15 Madeira Therapeutics - USA
10:30 Arzeda Corporation - USA
10:45 Cytox Limited - United Kingdom
11:00 Pepscan Therapeutics BV - Netherlands
11:15 Bellicum Pharmaceuticals, Inc - USA
11:30 Accera, Inc - USA
11:45 Somnus Therapeutics, Inc. - USA
12:00 Logical Therapeutics, Inc. - USA

12:15-1:15  Hot Lunch Buffet - Vineyard Terrace & Estate Wine Cave

Continue your networking over an invigorating hot lunch buffet of yellow tomato gazpacho with micro basil, tri-color lettuces with blue cheese, candied walnuts, and fresh fruit, roasted vegetables with cannellini beans and fennel, grilled chicken cacciatore with fresh tomato and garlic, and slow-roasted pork loin with sage butter. Complete your experience with tropical iced tea and a heartwarming helping of tiramisu.

1:15-3:15  Company Presentations - Stream 1 - Salon VI

In these dedicated presentations, biotechnology companies from around the world have the opportunity to briefly introduce their company, highlight key technologies, alliances, and where they stand with product & clinical developments.

1:15 BioAMPs International, LLC - USA
1:30 Acucela Inc. - USA
1:45 Syntaxin Ltd - United Kingdom
2:00 Pegasus Biologics - USA
2:15 Biotecnol Pharmaceuticals, Inc. - USA
2:30 NexThera Biosciences srl - Italy
2:45 CDG Therapeutics, Inc. - USA
3:00 Migco Pharmaceuticals - New Zealand

1:15-3:15  Company Presentations - Stream 2 - Salon IV

In these dedicated presentations, biotechnology companies from around the world have the opportunity to briefly introduce their company, highlight key technologies, alliances, and where they stand with product & clinical developments.

1:15 GeneIDs, Inc. - USA
1:30 SEA Medical Systems - USA
1:45 Tetraphase Pharmaceuticals - USA
2:00 Profectus BioSciences Inc. - USA
2:15 AvidBiotics Corp. - USA
2:30 NovaRx Corporation - USA
2:45 Reata Pharmaceuticals, Inc. - USA
3:00 Protagonist Therapeutics - USA

1:30-3:45  Presenting Company Tabletop Meetings - Salon II

Companies will be available for informal face-to-face meetings for 30 minutes immediately following their presentation time.

Company	Table #	Table Time
Acucela Inc.	3	1:45-2:15
AvidBiotics Corp.	4	2:30-3:00
BioAMPs International, LLC	1	1:30-2:00
Biotecnol Pharmaceuticals, Inc.	3	2:30-3:00
CDG Therapeutics, Inc.	1	3:00-3:30
GeneIDs, Inc.	2	1:30-2:00
Migco Pharmaceuticals	3	3:15-3:45
NexThera Biosciences srl	5	2:45-3:15
NovaRx Corporation	6	2:45-3:15
Pegasus Biologics	1	2:15-2:45
Profectus BioSciences Inc.	2	2:15-2:45
Protagonist Therapeutics	4	3:15-3:45
Reata Pharmaceuticals, Inc.	2	3:00-3:30
SEA Medical Systems	4	1:45-2:15
Syntaxin Ltd	5	2:00-2:30
Tetraphase Pharmaceuticals	6	2:00-2:30

4:00-5:15  Trends & Issues Session 4 - Salons III - VI

Title: Structuring Financings So Everyone Wins
In today's environment, companies must pursue all potential avenues for raising capital. Understanding your financing options is crucial. Join our panel of financial and strategic investors to discuss financings at the various stages in the life sciences company life cycle, from early stage financing to late stage down rounds, and how these transactions can be structured to maximize success for all parties involved. Key areas to be addressed include:

• Tranched financings
• Pay to play provisions
• Bridge financings
• Structured financings
• Debt financings
• Incentives for management
• Strategic investors

Chair: Mr. Bradley A. Bugdanowitz, Partner, Goodwin Procter LLP
Speaker: Ms. Kathy Conte, Managing Director, Hercules Technology Growth Capital
Speaker: Mr. Dion Madsen, Managing Director, Physic Ventures
Speaker: Mr. Paul Truex, President & CEO, Anthera Pharmaceuticals

4:00-5:15  Trends & Issues Session 5 - Salons VII - X

Title: How to “Fix” the Venture Investing Model

The financial markets are in disarray, having experienced a prolonged drop interspersed with substantial volatility. Investment capital has dried up. Cash is being returned to investors by some companies that cannot find a better way to deploy it or must placate hostile investors disappointed with results to date. New venture funds are hard to raise. Companies are cutting to the bone or failing or both.

Venture investors seem caught between the desire to fund innovation and the need to protect their best portfolio companies. Many venture firms have given up on early stage investing and are now focused solely on late stage opportunities, revenue companies, and VIPES/PIPES.

Whither the venture model? How has it evolved over the past decade? Has there been too much money chasing too few deals? Did venture investors fund too many companies and are we now seeing the Darwinian result? Were venture capitalists prepared for the current environment? Is the venture community partially responsible for the severity of the ongoing funding drought? How many venture capital firms will survive? What should a venture-backed CEO expect from the venture community?

The panel, comprised of experienced investors with substantial operating and investing experience, will analyze the current state of the venture model, explore the experience of the last several years and attempt to come up with answers to many of these questions. At the same time, the panel will take a critical look at where the venture model is headed and what needs to happen to “fix” this risk capital model and thus support a resurgent life sciences sector.

Chair: Mr. E. Hunterson Henrie, Managing Director, Ferghana Partners Group
Speaker: Mr. Brent Ahrens, General Partner, Canaan Partners
Speaker: Mr. Srini Akkaraju, Managing Director, New Leaf Venture Partners
Speaker: Dr. Deval A. Lashkari, Partner, Telegraph Hill Partners

5:15-6:15  Farewell Drinks Reception - Vineyard Terrace

An opportunity to say good-bye to fellow delegates and begin planning for the next C21 BioVentures conference scheduled May 25-27, 2010 at the Meritage Resort.